Developing the next generation of therapies for immune-mediated disease

PT-002 is a first-in-class small molecule drug which targets epigenetic enzymes involved in allergy.

 

Allergic disease is caused by hyperreactivity of the immune system to environmental allergens. These hyperreactions are caused by IgE antibodies.

 

Unlike existing allergy therapies, PT-002 acts to reprogram the immune response to allergens to reduce IgE production. This causes allergen tolerance leading to long-term symptomatic relief.